Literature DB >> 1094318

Clinical evaluation of eterobarb, a new anticonvulsant drug.

B B Gallagher, I P Baumel, S G Woodbury, J A Dimicco.   

Abstract

Two clinical investigations of a new anticonvulsant, eterobarb, N,N' dimethoxymethyl phenobarbital (DMMP), were conducted in separate geographic regions. The drug has considerable efficacy in reducing the frequency of partial seizures, with and without secondary generalization, as well as generalized tonic-clonic seizures. Sedation did not appear to be as prominent with this barbiturate as it was with phenobarbital or primidone.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1094318     DOI: 10.1212/wnl.25.5.399

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

1.  Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers.

Authors:  N Barzaghi; G Gatti; R Manni; C A Galimberti; C Zucca; E Perucca; A Tartara
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

2.  Two antiepileptic drugs for intractable epilepsy with complex-partial seizures.

Authors:  D Schmidt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-12       Impact factor: 10.154

Review 3.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.